Takeda launches sleep disorder pill in US after DEA clearance removes final hurdle
TAK•TAK•TAK•TAK•Takeda’s narcolepsy pill Orzeyful is available by prescription in the US after DEA clearance. The drug has a list price of $16,500 per 60-tablet bottle and will be dispensed through Cigna’s Accredo Specialty Pharmacy.
Takeda said Orzeyful, a twice-daily pill for narcolepsy type 1, is now available in the US after the DEA classified it as a Schedule IV controlled substance. The FDA approved the treatment in August.
The drug has a US list price of $16,500 per 60-tablet bottle across all strengths and will be dispensed by prescription through Cigna’s Accredo Specialty Pharmacy. Takeda said the condition affects about 120,000 people in the US.
Orzeyful targets the loss of orexin signaling that causes the disorder. In studies, it improved patients’ ability to stay awake during the day compared with placebo and significantly reduced episodes of cataplexy, a sudden muscle weakness triggered by strong emotions.
